Methotrexate in rheumatoid arthritis: A prospective study in Israeli patients with immunogenetic correlations

Moshe Tishler, Dan Caspi, Tal O. Rosenbach, Beno Fishel, Irena Wigler, Rafael Segal, Ephraim Gazit, Michael Yaron

Research output: Contribution to journalArticlepeer-review

Abstract

In a prospective open study 44 Israeli patients with rheumatoid arthritis were treated with weekly low dose methotrexate (MTX) for up to 36 months. Nine patients withdrew from the study: six because of side effects and three due to inefficacy. One patient died of septicaemia following septic arthritis. Significant improvement, graded by Ritchie articular index, grip strength, physician's global assessment, erythrocyte sedimentation rate (ESR), and platelet counts, was noticed in response to treatment. Seronegative patients had a better clinical response. Transient gastrointestinal symptoms were common and correlated with increases of serum aspartate transaminase (AST). HLA-DR1 and DR7 were significantly associated with increased serum AST concentrations.

Original languageEnglish
Pages (from-to)654-659
Number of pages6
JournalAnnals of the Rheumatic Diseases
Volume47
Issue number8
DOIs
StatePublished - 1988

Keywords

  • HLA antigens

Fingerprint

Dive into the research topics of 'Methotrexate in rheumatoid arthritis: A prospective study in Israeli patients with immunogenetic correlations'. Together they form a unique fingerprint.

Cite this